Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Lanreotide, non steroidal anti androgens and LHRH-a

"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."

DRUG

Non steroidal anti androgens and LHRH-a

Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression

Trial Locations (1)

Unknown

A.O. S. Luigi Gonzaga, Orbassano ( TO)

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY